Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
ASCO 2018: Integrating genomic data throughout treatment for prostate cancer

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 2292
Rating:

Prof Kurt Miller and Prof Bertrand Tombal

Prof Kurt Miller (Benjamin Franklin Medical Centre, Berlin, Germany) and Prof Bertrand Tombal (Cliniques Universitaire Saint Luc, Belgium) share their thoughts on the genomic data and its implications for prostate cancer treatment presented from day 1 at ASCO 2018.

They emphasise that taking a detailed family history of any breast cancer, ovarian cancer as well as prostate cancers is a vital first step for new patients.

Genetic counselling for ‘healthy’ family members needs to be considered alongside the role that geneticists versus urologists/oncologists play to ensure robust pathways and local working practices.

Emerging data indicates that 40% of BRCAm patients may not have a family history therefore somatic and liquid biopsy testing needs to be integrated into treatment pathways for new and existing patients who may progress whilst on treatment with abiraterone or enzalutamide. Currently patients may be screened for genetic mutations for clinical trial entry (BRCA and MSII), however with the future introduction of PARP and checkpoint inhibitors this will become more routine and will be an important consideration for all specialists to start to consider for prostate cancer patients.

 

Genomic counselling for prostate cancer risk
Somatic testing and liquid biopsy
Tumour biopsy v liquid biopsy
Who and when to genetically sequence


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation